Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics
Keenova Focused on Advancing Therapies to Address Unmet Patient Needs Company Intends to Pursue Public Equity Listing in 2026 Mallinckrodt plc (“Mallinckrodt”) today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses. Moving ahead, Mallinckrodt will be known as Keenova Therapeutics (“Keenova” or the “Company”) and will […]